Addition of ADT and Pelvic Lymph Node Radiotherapy to Salvage Prostate Bed Radiotherapy After Prostatectomy
In a phase III trial (NRG Oncology/RTOG 0534 SPPORT) reported in The Lancet, Alan Pollack, MD, PhD, and colleagues found that both the addition...
CoVac-1 Vaccination Studied for Prevention of Severe COVID-19 in Immune-Deficient Patients With Cancer
CoVac-1, a multipeptide COVID-19 vaccine candidate, elicited immunogenicity in patients with cancer and disease-related or treatment-related...
Addition of Vistusertib to Anastrozole for Hormone Receptor–Positive Recurrent or Metastatic Endometrial Cancer
In a French phase I/II trial (VICTORIA) reported in JAMA Oncology, Heudel et al found that the addition of the mTOR inhibitor vistusertib...
Neurologic and Survival Outcomes After Awake Craniotomy for Glioblastoma
In an analysis from the GLIOMAP study reported in The Lancet Oncology, Gerritsen et al found that awake craniotomy for glioblastoma...
ASCO Coronavirus Resources
As the coronavirus (COVID-19) continues to spread, ASCO is committed to providing the most current information and resources to its members and the larger oncology...
Matthew L. Meyerson, MD, PhD, on Lung Adenocarcinoma: Somatic Mutations, Germline Risk, and Ancestry
Louis Staudt and Wyndham Wilson: Phase III Trials and Tribulations
Lisa Carey: Immune Checkpoint Inhibitors in Neoadjuvant or Adjuvant Therapy for TNBC
Rachel Grisham: MEK Inhibition Is Now a Standard of Care in Recurrent Low-Grade Serous Ovarian Cancer
James Smithy and Margaret Callahan: Relatlimab Plus Nivolumab Worthy of Further Study in Advanced Melanoma and Beyond
Neal Meropol: Reflections on the Evolution of Clinical Care Since the Passage of the National Cancer Act
Sponsored Content
Sponsored by Helsinn
Practical Issues in the Use of FGFR Inhibitors for Advanced Cholangiocarcinoma
Sponsored by Adaptive Biotechnologies
The Role of Minimal Residual Disease Assessment in Guiding Personalized Care in Multiple Myeloma
Sponsored by Pfizer Medical Affairs
Considerations in the Front-Line Treatment of Hormone Receptor–Positive/HER2-Negative Advanced Breast Cancer
ADAPT: Survival Outcomes After Neoadjuvant Dual HER2 Therapy for HR-Negative, HER2-Positive Breast Cancer
The first overall survival analysis of the WSG-ADAPT HR-/HER2+ study, which evaluated neoadjuvant therapy in patients with hormone receptor (HR)-negative, HER2-positive breast cancer, showed that treatment with pertuzumab and trastuzumab plus paclitaxel—or the chemotherapy-free regimen of...
Impact of Genes on Total Number and Type of Nevi
A study by Duffy et al in the Journal of Investigative Dermatology reported on specific gene variations affecting the number and types of moles on the body and their role in causing skin cancer. “The goal was to investigate the genetic underpinnings of different mole classes, or...
ADAPT: Survival Outcomes After Neoadjuvant Dual HER2 Therapy for HR-Negative, HER2-Positive Breast Cancer
The first overall survival analysis of the WSG-ADAPT HR-/HER2+ study, which evaluated neoadjuvant therapy in patients with hormone receptor (HR)-negative, HER2-positive breast cancer, showed that treatment with pertuzumab and trastuzumab plus paclitaxel—or the chemotherapy-free regimen of...
Axicabtagene Ciloleucel Demonstrates Improvement Across Multiple Endpoints in Relapsed or Refractory Follicular Lymphoma
In the treatment of relapsed/refractory follicular lymphoma, a comparison of data from the ZUMA-5 trial with those of the external control cohort of the SCHOLAR-5 trial showed substantial improvement in all clinical endpoints with axicabtagene ciloleucel. John G. Gribben, DSc, FRCP, FRCPath,...
Gemcitabine/Eribulin in Cisplatin-Ineligible Metastatic Urothelial Carcinoma
In the final analysis from a phase II California Cancer Consortium trial (NCI-9653) reported in the Journal of Clinical Oncology, Sadeghi et al found the combination of gemcitabine and eribulin showed activity in cisplatin-ineligible patients with metastatic urothelial carcinoma. Study Details...
Remote Monitoring Program Reduced Hospitalization Among Patients With Cancer Infected With COVID-19
A study by researchers at Mayo Clinic Cancer Center found that patients with cancer diagnosed with COVID-19 who received care at home via remote patient monitoring were significantly less likely to require hospitalization for their illness, compared to patients with cancer infected with the virus...
Deintensified Chemoradiotherapy for HPV-Associated Oropharyngeal Squamous Cell Carcinoma
In a phase II trial reported in the Journal of Clinical Oncology, Chera et al found that deintensified chemoradiotherapy produced favorable outcomes in human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma. Study Details In the multicenter trial, 114 patients were recruited...
